Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Gross Profit (2016 - 2025)

Historic Gross Profit for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $111.7 million.

  • Ligand Pharmaceuticals' Gross Profit rose 12620.18% to $111.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236.8 million, marking a year-over-year increase of 6615.15%. This contributed to the annual value of $156.1 million for FY2024, which is 2918.58% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Gross Profit stood at $111.7 million, which was up 12620.18% from $44.7 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Gross Profit's 5-year high stood at $111.7 million during Q3 2025, with a 5-year trough of $24.7 million in Q2 2023.
  • Moreover, its 5-year median value for Gross Profit was $40.0 million (2024), whereas its average is $41.9 million.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 3523.64% in 2022, then surged by 12620.18% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Gross Profit stood at $44.4 million in 2021, then tumbled by 35.24% to $28.8 million in 2022, then fell by 8.02% to $26.5 million in 2023, then soared by 51.08% to $40.0 million in 2024, then soared by 179.32% to $111.7 million in 2025.
  • Its Gross Profit was $111.7 million in Q3 2025, compared to $44.7 million in Q2 2025 and $40.5 million in Q1 2025.